LNS8801,GPER,,TGS

Christina Marinaro1,2, John Sauer1,3, Christopher A Natale4,5

  • 1Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, The State University of New Jersey, New Brunswick, New Jersey, USA.

PubMed
概括

这项研究研究了LNS8801,一种与G蛋白结合的雌激素受体激活剂,用于小鼠黑色素瘤治疗. LNS8801证明了性别偏差的有效性,并提供了对黑色素瘤进展的紫外线保护.